ArticleFrontiers in immunology2022
A multi-epitope vaccine GILE against
Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Current Efficacy of Multiepitope Vaccines Against Helminths: A Systematic Review.Biomolecules · 2025Pooled it
- Characterization of 2-deoxyribose-5-phosphate aldolase from Bacillus altitudinis JYY-02.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026Article
- Polarization of Hepatic Macrophages in Alveolar Echinococcosis and Its Role in Remodeling the Immune Microenvironment.Tropical medicine and infectious disease · 2026Review
- Effect of antiserum against recombinant EGr_09888 on the in vitro development of Echinococcus granulosus protoscoleces.Parasitology research · 2025Article
- A Highly Immunogenic and Cross-Reactive Multi-Epitope Vaccine Candidate Against Duck Hepatitis A Virus: Immunoinformatics Design and Preliminary Experimental Validation.International journal of molecular sciences · 2025Article
- Intracellular Parasitic Infections Caused byVaccines · 2025Review
- Immunogenicity Evaluation of Epitope-Based Vaccine on Target of RNAIII-Activating Protein (TRAP) ofBiology · 2025Article
- Article
- Evaluation of a multi-epitope vaccine PME forFrontiers in immunology · 2025Article
- Efficacy and safety of pseudolaric acid B againstFrontiers in medicine · 2025Article
- Current status and future prospects ofVeterinary and animal science · 2024Review
- Immunoprotective effect and mechanism of rEg.P29 against CD4Acta biochimica et biophysica Sinica · 2024Article
- Novel dual-pathogen multi-epitope mRNA vaccine development for Brucella melitensis and Mycobacterium tuberculosis in silico approach.PloS one · 2024Article
- Design of a novel EmTSP-3 and EmTIP based multi-epitope vaccine againstFrontiers in immunology · 2024Article
- Oral Immunization with AttenuatedBiomolecules · 2023Article
- Basic Operative Tactics for Pulmonary Echinococcosis in the Era of Endostaplers and Energy Devices.Medicina (Kaunas, Lithuania) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The objective of this study is to construct a multi-epitope vaccine GILE containing B-cell and T-cell epitopes against Methods: The structure and hydrophobicity of GILE were predicted by SWISSMODEL, pyMOL, SOPMA and VMD, and its sequence was optimized by Optimum™ Codon. The GILE gene was inserted into pCzn1 and transformed into Results: The SWISS-MODEL analysis showed that the optimal model was EMY162 Discussion: A multi-epitope vaccine GILE with good immunogenicity and antigenicity has been successfully constructed in this study, which may provide important theoretical and experimental bases for the prevention and treatment of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.